# Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

> **NCT06085755** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jeeyun Lee** · enrollment: 61 (estimated)

## Conditions studied

- Stomach Neoplasm

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT06085755
- **Lead sponsor:** Jeeyun Lee
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06085755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06085755, "Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06085755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*